This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
5 Promising Growth Stocks in MedTech to Invest in 2020
by Trina Mukherjee
We have zeroed in on five impressive growth stocks in MedTech on the back of the industry's lucrative prospects.
Invest in These 5 Low Leverage Stocks Before Q4 Earnings
by Zacks Equity Research
Companies displaying high earnings growth along with high leverage ratios should be avoided while making investment decisions. So, investors should select companies with low leverage.
Varian (VAR) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Varian (VAR) gains from several positive developments.
Amedisys Gains on Favorable Demography, New Hospice Buyouts
by Zacks Equity Research
Amedisys (AMED) is steadily benefiting from its recent takeovers of hospice care providers, namely RoseRock Healthcare and Compassionate Care Hospice.
Exact Sciences Rides on Cologuard, Eyes Merger Synergies
by Zacks Equity Research
Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.
Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging
by Zacks Equity Research
The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.
Here's Why You Should Add STERIS (STE) to Portfolio Now
by Zacks Equity Research
Investor confidence is high on STERIS (STE) stock for now, thanks to its solid prospects.
LabCorp (LH) Grows on Solid Diagnostics Arm Despite PAMA Headwinds
by Urmimala Biswas
LabCorp's (LH) Diagnostics business flourishes organically in terms of both revenues and volumes despite additional price reductions due to Protecting Access to Medicare Act (PAMA).
Here's Why You Should Hold on to Phibro (PAHC) Stock Now
by Zacks Equity Research
Investors can retain Phibro (PAHC) stock for now, thanks to its solid prospects.
Illumina Stock Slips on Pacific Biosciences Deal Termination
by Zacks Equity Research
Per Illumina (ILMN), the lengthy route to achieve regulatory nods for the transaction induces uncertainty about the ultimate outcome of the integration.
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
by Zacks Equity Research
Investors can retain QIAGEN (QGEN) stock for now, thanks to its solid prospects.
Here's Why You Should Hold on to Insulet (PODD) Stock Now
by Zacks Equity Research
Investors can retain Insulet (PODD) stock for now on the back of its solid prospects.
Here's Why You Should Hold on to Intersect ENT (XENT) for Now
by Zacks Equity Research
Investors can retain Intersect ENT (XENT) stock for now, courtesy of its solid prospects.
Bio-Rad Gains on New Product Portfolio Despite Currency Woes
by Zacks Equity Research
Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Syneos Health (SYNH) gains from several positive developments.
Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education
by Zacks Equity Research
Zacks.com featured highlights include: Johnson & Johnson, Gibraltar Industries, Omnicell, MDU Resources and Career Education
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investors can retain Hill-Rom (HRC) in their portfolio, courtesy of solid prospects.
Bet on These 5 Low Leverage Stocks to Invest Judiciously
by Zacks Equity Research
Debt level of a company is an important point of consideration while making an investment decision.
ResMed (RMD) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
ResMed (RMD) gains from impressive performance of its SaaS business.
Here's Why You Should Add Omnicell to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Omnicell (OMCL) is at a high, thanks to solid prospects.
Omnicell-Huron Sign a Pact for Outcome-Based Expert Services
by Zacks Equity Research
Omnicell (OMCL) partners Huron to provide customers with committed expertise.
Worried About Market Downturn? Buy These Low Leverage Stocks
by Zacks Equity Research
Debt is a much cheaper form of financing than equity. Yet the fact that debt carries the burden of interest payments makes it dearer.
Omnicell (OMCL) Partners With Kit Check to Offer Bluesight
by Zacks Equity Research
This partnership will offer Omnicell (OMCL) the state-of-the art technology and medication intelligence needed to ensure accurate delivery of drugs to the right patients.
Omnicell to Feature Upgrades in Medication Management at ASHP
by Zacks Equity Research
Omnicell (OMCL) to showcase innovations in medication management solution portfolio to minimize human errors by care providers.
Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education
by Zacks Equity Research
Zacks.com featured highlights include: Manulife, Gibraltar, Omnicell, SolarEdge and Career Education